Drug Profile
Research programme: HIV entry inhibitors - Ambrilia Biopharma
Latest Information Update: 10 Jul 2013
Price :
$50
*
At a glance
- Originator Ambrilia Biopharma
- Class Small molecules
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 09 Jul 2013 Discontinued for HIV infections in Canada prior to 9 July 2013 (unspecified route)
- 07 Jan 2011 Early research in HIV infections in Canada (unspecified route)